Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aleglitazar: Development discontinued

Roche discontinued development of aleglitazar after an independent DSMB recommended stopping early the international Phase III

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE